Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 16:13:1186503.
doi: 10.3389/fonc.2023.1186503. eCollection 2023.

Acute kidney injury and chronic kidney disease in umbilical cord blood transplant recipients

Paolo Lopedote  1 , Elisabetta Xue  2 , Julie Chotivatanapong  3 , Emily C Pao  3 , Chiara Wychera  3 , Ann E Dahlberg  3 , Laurel Thur  3 , Laura Roberts  3 , Kelsey Baker  3 , Ted A Gooley  3 , Sangeeta Hingorani  3   4 , Filippo Milano  3
Affiliations

Acute kidney injury and chronic kidney disease in umbilical cord blood transplant recipients

Paolo Lopedote et al. Front Oncol. .

Abstract

Introduction: Acute kidney injury (AKI) is a frequent early complication post hematopoietic stem cell transplant (HSCT), associated with high morbidity and mortality. Cord blood transplant (CBT) recipients are potentially exposed to more nephrotoxic insults, compared to patients undergoing HSCT from other donor sources. We aimed to identify risk factors for AKI in patients undergoing CBT. We also aimed to identify the impact of AKI on chronic kidney disease (CKD) and survival outcomes by one-year post-CBT.

Methods: Adults and children who underwent a first CBT at our Institution were retrospectively evaluated. AKI was staged according to Kidney Disease Improving Global Outcomes (KDIGO) definitions. Cox regression models were used to estimate the association of demographic factors and post-CBT parameters with the cause-specific hazard of AKI.

Results: We identified 276 patients. Median age was 32 years, 28% (77/276) were children (<18 years) and 129 (47%) were white. A myeloablative conditioning regimen was administered to 243 patients (88%) and 248 (90%) received cyclosporine for GVHD prophylaxis. One-hundred and eighty-six patients (67%) developed AKI by day 60 post-transplant, with 72 (26%) developing severe AKI (stage 2 and 3). In a multivariable analysis, each increase in bilirubin level of 1 mg/dL was associated with a 23% increase in the risk of severe AKI (adjusted HR 1.23, 95% CI 1.13 - 1.34, p<.0001). Conversely, systemic steroid administration appeared to be protective of severe AKI (unadjusted HR 0.36, 95% CI 0.18 - 0.72, p=.004) in a univariate model . Two-hundred-forty-seven patients were evaluable at the one-year time point. Among those, 100 patients (40%) developed CKD one-year post-CBT. Severe AKI was associated with a higher hazard of non-relapse mortality (adjusted HR=3.26, 95% CI 1.65-6.45, p=.001) and overall mortality (adjusted HR=2.28, 95% CI 1.22-4.27, p=.01).

Discussion: AKI is a frequent complication after CBT and is associated with worse outcomes. Questions remain as to the mechanism of the protective role of steroids on kidney function in the setting of CBT.

Keywords: acute kidney injury (AKI); allogenic stem cell transplantation; bilirubin; chronic kidney disease (CKD); cord blood transplantation (CBT); graft versus host disease (GVHD); steroid.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Landmark analysis showing overall survival since day 60 post-transplant for patients who developed any grade AKI (blue line) and no AKI (red line). Abbreviations: AKI, acute kidney injury.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Ponce DM, Gonzales A, Lubin M, Castro-Malaspina H, Giralt S, Goldberg JD, et al. . Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match. Biol Blood Marrow Transplant (2013) 19(6):904–11. doi: 10.1016/j.bbmt.2013.02.008 - DOI - PMC - PubMed
    1. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, et al. . Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med (2004) 351(22):2265–75. doi: 10.1056/NEJMoa041276 - DOI - PubMed
    1. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. (2013) 122(4):491–8. doi: 10.1182/blood-2013-02-453175 - DOI - PMC - PubMed
    1. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, et al. . Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med (1998) 339(22):1565–77. doi: 10.1056/NEJM199811263392201 - DOI - PubMed
    1. Ruggeri A, Labopin M, Sormani MP, Sanz G, Sanz J, Volt F, et al. . Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen. Haematologica. (2014) 99(9):1509–15. doi: 10.3324/haematol.2014.109280 - DOI - PMC - PubMed

LinkOut - more resources